Reason for request
Inclusion on list of products reimbursed by National Insurance and for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of FIRMAGON is substantial. |
Clinical Added Value
| no clinical added value |
In the context of the current strategy for treatment of advanced prostate cancer, with a combination of a Gn-RH analogue and an antiandrogen in the first month of treatment, FIRMAGON provides no improvement in actual benefit (IAB level V). |
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
Vt0jxCbXd6M5SQNC
